Neuroscience

#Alzheimer's #Cancer immunotherapy #Cancer research #Dermatology #Drug development #Drug discovery #Genetics / genomics #Immunology / Virology & Vaccines #Immunotherapy #Monoclonal antibodies #mRNA

Listen now: Last episode of DDW Highlights for 2022

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The focus has been on immunotherapy and genetics this week, with exciting… Read More

#News

#Alzheimer's #Cancer immunotherapy #Cancer research #Dermatology #Drug development #Drug discovery #Genetics / genomics #Immunology / Virology & Vaccines #Immunotherapy #Monoclonal antibodies #mRNA

This week in drug discovery (12-16 December)

News round-up for 12-16 December by DDW Digital Content Editor Diana Spencer. The focus has been on immunotherapy and genetics this week, with exciting developments in the treatment of multiple myeloma, atopic dermatitis, Alzheimer’s, late-stage melanoma and acute myeloid leukaemia.  The top stories: … Read More

#News

Human neurone
#Biosciences #Genetic diseases #Ion channels #Neurology #Neuroscience #Rare disease #Therapeutics

Ion channel modulators for ultra-rare genetic disorder 

Metrion Biosciences, a specialist ion channel contract research and drug discovery company, and The KCNC1 Foundation, a not-for-profit organisation focused on the development of a treatment for an ultra-rare genetic disorder, have entered a collaboration to progress a hit identification research project for small molecule modulators of the potassium… Read More

#News

#Alzheimer's #Neurodegenerative disorders #Neuroscience

Novel peptide targets early molecular trigger of Alzheimer’s

A new study has demonstrated the ability of a novel peptide to selectively detect and neutralise an early molecular trigger of Alzheimer’s and other neurodegenerative diseases.  The Proceedings of the National Academy of Sciences (PNAS) will publish results of the groundbreaking study demonstrating a customised,… Read More

#Editor's Choice #News

#Cancer research #Covid-19 #Depression #Drug development #Drug discovery #FDA #Gene therapy #Malaria #Neuroscience #Olfactory disorders #Prostate cancer

Podcast: Keep up-to-date on the latest industry news

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news.  The industry has seen breakthroughs announced in malaria treatment, epilepsy and major… Read More

#News

#Cancer research #Covid-19 #Depression #Drug development #Drug discovery #FDA #Gene therapy #Malaria #Neuroscience #Olfactory disorders #Prostate cancer

This week in drug discovery (28 November – 2 December)

News round-up for 28 November – 2 December by DDW Digital Content Editor Diana Spencer  The last seven days have seen breakthroughs announced in malaria treatment, epilepsy and major depressive disorders. The NHS in England has fast tracked another cancer drug, and, in Covid-19 news, researchers have… Read More

#News

Psychiatrist with patient
#Major depressive disorder #Neuroscience #Phase I trial

Injectable drug could offer new option for depressive disorders

The first subject has been dosed in a Phase I biomarker study of apimostinel, a rapid-acting N-methyl-D-aspartate receptor (NMDAR) modulator for major depressive disorders (MDD).  The injectable treatment was developed by clinical-stage biotechnology company Gate Neurosciences for acute depressive disorders… Read More

#News #Trending News

MRI of the brain
#epilepsy #Mouse models #Neuroinflammation #Neuroscience

Neuroscientists discover new drug candidate for treating epilepsy

Neuroscientists have identified and developed a new drug candidate that has the potential to effectively treat temporal lobe epilepsy (TLE) by suppressing neuroinflammation.  Although symptomatic medications are available, one-third of TLE patients remain unresponsive to current treatment, so new drug targets are critically needed. Most of these… Read More

#News #Trending News

Big Ben and Houses of Parliament
#Cancer research #Drug discovery #Funding #Mental health #UK government

Cancer research to get £22.5 million share of UK fund

The UK government has promised that patients will benefit from cutting-edge new treatments with the introduction of a Vaccine Taskforce style approach to tackling health challenges.  The government has committed over £113 ($135) million to fund research into four healthcare missions – cancer, obesity, mental health and addiction. Building… Read More

#Cancer Research #News

#Cancer research #Diabetes #Drug development #Drug discovery #FDA #Gene therapy #Haemophilia #MHRA #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders

News update available on DDW Highlights podcast

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news.  Gene therapies have made the headlines over the last week, with treatments… Read More

#News

#Cancer research #Diabetes #Drug development #Drug discovery #FDA #Gene therapy #Haemophilia #MHRA #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders

This week in drug discovery (21-25 November)

News round-up for 21-25 November by DDW Digital Content Editor Diana Spencer  Gene therapies have made the headlines over the last few days, with treatments for rare AADC deficiency, lung cancer and haemophilia B given the go ahead from regulators. This week has also seen the first… Read More

#News

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Animal models #Neurodegenerative disorders #University of Glasgow

Hope for drug that slows neurodegenerative disease

Scientists have found a new drug treatment that can slow the progression of neurodegenerative disease in mice. The breakthrough research may offer fresh hope in tackling currently untreatable conditions such as Alzheimer’s disease (AD).  The study was led by researchers at the University of Glasgow’s new Advanced… Read More

#Editor's Choice #News

Discovery Park, Kent
#Life sciences #Neuroscience #Pfizer #Science and innovation park

UK Discovery Park plans centre of excellence for neuroscience

One the UK’s largest science and innovation parks has revealed plans to double in size as it celebrates its ten-year anniversary. Discovery Park, based near Sandwich in Kent, marked the milestone by announcing its plans for the next ten years, which include the creation of a national centre of excellence… Read More

#News

5-Methoxy-N, N-Dimethyltryptamine
#Phase I trial #Psychedelics #Psychiatry #Treatment-resistant depression

Synthetic psychedelic successfully completes Phase I study 

Beckley Psytech has completed its Phase I clinical study of BPL-003, a synthetic intranasal formulation of 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT).  The drug is under development for Treatment Resistant Depression and Alcohol Use Disorder and was assessed in combination with psychological support in 44 psychedelic-naïve participants.  Initial… Read More

#News

Neurons in the brain
#Drug discovery #In vitro assays #Multiple sclerosis #Neurodegenerative disorders #Neuronal damage #Target identification #Webinar

Webinar: Innovative assays for neurodegeneration drug discovery

Neurodegenerative diseases are characterised by neuronal damage, degradation of the blood-brain barrier and failures in the normal repair mechanisms of the brain. Many of the most promising areas of drug development in this field target neuroinflammation and remyelination. In this new on-demand webinar we use multiple sclerosis as a case-study… Read More

Webinar date:
Brought to you by Malvern Panalytical
#News

#Covid-19 #Geographic atrophy #Immunology / Virology & Vaccines #Malaria #Neuroscience #Psychedelics

Catch up on the latest DDW Highlights episode

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  In a week that saw magic mushrooms making the… Read More

#News